表紙
市場調查報告書
商品編碼
1084464

原發性硬化性膽管炎的全球市場:市場規模,佔有率,趨勢,預測(2022年∼2028年)

Primary Sclerosing Cholangitis Market - Size, Share, Trends, and Forecast, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 134 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球原發性硬化性膽管炎的市場規模,由於著重臨床創新的組織增加,理解原發性硬化性膽管炎的機制和風險因素的相關科學性進步,大學和製藥企業的臨床試驗和臨床試驗前增加等所促進。

本報告提供全球原發性硬化性膽管炎市場調查,市場概要,市場規模和預測,趨勢,成長要素,阻礙因素,各藥物、地區的分析,及競爭情形等資訊。

目錄

第1章 調查目的、前提條件

  • 調查目的
  • 假設
  • 簡稱

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場概要
    • 樂觀的,可能性的高,及悲觀的概要

第3章 市場動態,開發平台,及PEST分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • PEST分析
  • 開發平台分析
  • 以支援和調查PSC為焦點的舉措
  • 階段3藥物中止的理由
  • 面臨的課題:罕見疾病用醫藥品
  • 流行病學

第4章 全球原發性硬化性膽管炎市場:各藥物

  • 簡介
  • BTT1023
  • GS-9674
  • NGM282
  • OCA
  • Cenicriviroc
  • LUM001
  • DUR928
  • norUDCA
  • HTD1801
  • IDN-7314
  • STP705

第5章 全球原發性硬化性膽管炎市場:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第6章 競爭情形

  • 企業簡介
    • Acorda Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • NGM Biopharmaceuticals, Inc.
    • Intercept Pharmaceuticals, Inc.
    • Dr. Falk Pharma GmbH
    • Allergan Plc.
    • Shire Plc.
    • Durect Corporation
    • Conatus Pharmaceuticals, Inc.
    • Sirnaomics, Inc.
    • Shenzhen HighTide Biopharmaceutical Ltd.
  • 分析師的見解

第7章 Section

目錄
Product Code: CMI1960

Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations. The drug segment will provide quick snapshot about the clinical phase of the study, study outcomes, estimated launch date, and the upcoming drug molecules. Moreover, the report entails information regarding the major events taking place in the global market, thereby gaining insights about drug approvals, merger agreements, and acquisitions undertaken by the manufacturing companies. Also, incidence and prevalence of PSC and its associated conditions at regional as well as global level are provided in the report, thereby indicating the total number of addressable patient pool in the respective regions and market opportunity for the same.

Market Dynamics

Major factors that are expected to augment growth of the primary sclerosing cholangitis market include increasing number of organizations focusing on clinical innovation and scientific progress on understanding the mechanisms and risk factors for primary sclerosing cholangitis (PSC). For instance, the International PSC study group (IPSCSG), founded in 2010, aims to coordinate PSC research projects between leading institutions worldwide, thereby allowing feasible translational research and advancing efficient research. Also, increasing number of clinical and preclinical trials conducted by the research universities and pharmaceuticals companies is expected to favor market growth over the forecast period.

However, failure of drug candidates to provide desired study outcomes and the withdrawal of late phase clinical trials of potential drug molecules are factors hindering the market growth.

Key features of the study:

This report provides in-depth analysis of primary sclerosing cholangitis market and provides pipeline analysis for the same

It elucidates potential opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global primary sclerosing cholangitis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans

Key companies covered as a part of this study include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

The global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the primary sclerosing cholangitis market

Detailed Segmentation:

Global Primary Sclerosing Cholangitis Market, By Drug:

BTT1023

GS-9674

NGM282

OCA

Cenicriviroc

LUM001

DUR928

norUDCA

HTD1801

IDN-7314

STP705

Global Primary Sclerosing Cholangitis Market, By Region:

North America

Regional Overview

Latin America

Regional Overview

Europe

Regional Overview

Asia Pacific

Regional Overview

Middle East

Regional Overview

Africa

Regional Overview

Company Profiles

Acorda Therapeutics, Inc.*

Company Overview

Product Portfolio

Financial Performance

Key Strategies

Recent Developments

Gilead Sciences, Inc.

NGM Biopharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Dr. Falk Pharma GmbH

Allergan Plc.

Shire Plc.

Durect Corporation

Conatus Pharmaceuticals, Inc.

Sirnaomics, Inc.

Shenzhen HighTide Biopharmaceuticals Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Overview
    • Optimistic, Likely and Pessimistic Overview

3. Market Dynamics, Pipeline, and PEST Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • PEST Analysis
  • Pipeline Analysis
  • Initiatives Focusing On PSC Support And Research
  • Reason For Phase 3 Drug Withdrawal
  • Challenges Faced by Orphan Drug Candidates
  • Epidemiology

4. Global Primary Sclerosing Cholangitis Market, By Drug

  • Introduction
  • BTT1023
    • Research Details
  • GS-9674
    • Research Details
  • NGM282
    • Research Details
  • OCA
    • Research Details
  • Cenicriviroc
    • Research Details
  • LUM001
    • Research Details
  • DUR928
    • Research Details
  • norUDCA
    • Research Details
  • HTD1801
    • Research Details
  • IDN-7314
    • Research Details
  • STP705
    • Research Details

5. Global Primary Sclerosing Cholangitis Market, By Region

  • Introduction
  • North America
    • Regional Overview
  • Latin America
    • Regional Overview
  • Europe
    • Regional Overview
  • Asia Pacific
    • Regional Overview
  • Middle East
    • Regional Overview
  • Africa
    • Regional Overview

6. Competitive Landscape

  • Company Profiles
    • Acorda Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Gilead Sciences, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • NGM Biopharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Intercept Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dr. Falk Pharma GmbH
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Allergan Plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Shire Plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Durect Corporation
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Conatus Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sirnaomics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Shenzhen HighTide Biopharmaceutical Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

7. Section

  • References
  • Research Methodology
  • About us and Sales Contact